We have read with interest the article by Nakaoka and colleagues1 on the efficacy and safety of tocilizumab in patients with refractory Takayasu arteritis. The authors have presented a randomised controlled trial in which they suggest a preference for tocilizumab over placebo for time to relapse of Takayasu arteritis, without any new safety concerns. We would like to draw attention to a few points in this regard. First, Takayasu arteritis and giant cell arteritis share some similarities in terms of …

中文翻译：

---

托珠单抗治疗难治性高安动脉炎患者的疗效和安全性

我们饶有兴趣地阅读了 Nakaoka 及其同事 1 关于托珠单抗在难治性高安动脉炎患者中的疗效和安全性的文章。作者提出了一项随机对照试验，在该试验中，他们建议在没有任何新的安全性问题的情况下，在高安动脉炎复发的时间上优先选择托珠单抗而不是安慰剂。我们想提请注意这方面的几点。首先，高安动脉炎和巨细胞动脉炎在……